Biologics
Taiwan Universe BioMedicine Inc.
Pipelines & Platforms
- Next-Gen Virus-Like Particle Influenza Vaccines (e.g., seasonal influenza and influenza H5N1): Disruptive 12-week rapid manufacturing with BSL-1 safety, superior immunogenicity, and low cost.
- Bivalent Enterovirus (EV71 & CVA16)
Vaccine: genetic platforms for preparing high-growth viruses, enabling highly
cost-effective and scalable production for the Asian market.
Interests
- Clinical Trial Collaboration
- Co-Development
- Out-Licensing
- Strategic Alliance
Contact Information
- NameMinshi Lee
- PositionCEO
- Tel+886-963-094961
- Emailminshi@nhri.edu.tw
- https://taiutw.com/